TWST

Over the past six months (April to October 2026), Twist Bioscience's stock (TWST) experienced significant movements, including a 400.16% increase over the last 12 months and a 24.80% increase in the past month, reaching an all-time high of $219.71 on October 5, 2026. In October 2026, the company announced an agreement with Eli Lilly's AI/ML TuneLab platform to provide antibody characterization data and services, positioning TWST as a data supplier to the AI drug discovery sector. Following this news, analysts from Leerink and Guggenheim raised their price targets, while UBS initiated coverage with a Neutral rating. On October 5, 2026, CEO Emily M. Leproust and CAO Robert Werner sold shares, leading to a 15% stock decline over the week. The stock had previously skyrocketed in early summer 2026, with its market cap jumping from approximately $1.7 billion to around $12 billion, attributed to AI enthusiasm and a potential short squeeze. In April 2026, Twist Bioscience reached a $17.05 million settlement with investors over misleading claims about its business operations, manufacturing, and product quality, stemming from a November 2022 report by Scorpion Capital.